Re: Still waiting for that BETonMACE CKD sub-study 7 months later
in response to
by
posted on
Jun 12, 2020 02:15PM
Barsax,
" believe we will have an opportunity for an early trial halt due to overwhelming efficacy."
Exactly. The key is to hone in on the patient group in which apabetalone works well, because it works really, really well in them. And RVX knows which patient group that is now. Also, use of biomarker endpoints could really speed things up - less waiting for non-existent MACE to happen.
Jupe